Kraig Biocraft Laboratories announced a large hiring program on November 25, 2025 to support the expansion of its spider‑silk production footprint in Southeast Asia. The company will recruit and train a new workforce under the guidance of Dr. Nirmal Kumar, a leading sericulture expert, to prepare for the opening of a third production facility in Lam Dong Province, Vietnam.
The hiring initiative comes as the company reports a net loss of $1.51 million for the third quarter of 2025, a sharp increase from the $433,200 loss recorded a year earlier. The widening loss reflects higher operating expenses associated with scaling production and the capital outlay required to build the new facility. To shore up liquidity, Kraig has secured a standby equity purchase agreement with YA II PN, LTD., allowing it to sell up to $10 million of common stock if needed.
Strategically, the expansion is a key step toward the company’s goal of delivering commercial spider‑silk fibers in the second half of 2025. By adding trained personnel and a new production line, Kraig aims to increase throughput and reduce per‑unit costs, positioning it to meet the growing demand from high‑performance textile and specialty‑fiber customers. The involvement of Dr. Kumar underscores the company’s commitment to leveraging expert sericulture knowledge to optimize yield and quality.
CEO Kim Thompson emphasized the initiative’s importance, stating, “This hiring initiative reflects the incredible momentum we are building and the strength of our forward‑looking production strategy. As we scale up our next‑generation spider‑silk technology and expand our production footprint, we are focused on assembling a team capable of supporting the high growth trajectory we anticipate.”
The hiring push is complemented by a recent order from a globally recognized performance‑sports apparel brand, a milestone that validates the commercial viability of Kraig’s spider‑silk yarns. The order is expected to generate early revenue streams and serve as a proof of concept for future large‑scale contracts.
While the company’s net loss signals short‑term financial pressure, the expansion and early commercial orders suggest a long‑term upside. The capital raise and workforce investment indicate management’s confidence in scaling production to meet anticipated demand, even as the company navigates the cost challenges inherent in pioneering a new biomanufacturing platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.